Brief: Pieris Pharmaceuticals Reports Q1 Results
May 10 (Reuters) - Pieris Pharmaceuticals Inc PIRS.O :
* PIERIS PHARMACEUTICALS REPORTS FIRST QUARTER 2023
FINANCIAL
RESULTS AND BUSINESS UPDATES
* PIERIS PHARMACEUTICALS INC - CASH, CASH EQUIVALENTS, AND
INVESTMENTS TOTALED $48.4 MILLION FOR THE QUARTER ENDED MARCH
31, 2023
* PIERIS PHARMACEUTICALS INC - BELIEVES OPERATIONS ARE
SUFFICIENTLY FUNDED FOR MORE THAN THE NEXT 12 MONTHS
* PIERIS PHARMACEUTICALS INC- QTRLY LOSS PER SHARE $0.45
Source text for Eikon: ID:
Further company coverage: PIRS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palvella Therapeutics
See all newsPalvella Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Palvella Therapeutics Q2 net loss widens on higher expenses
Brief: Palvella Therapeutics Announces New Data From The Phase 2 Toiva Trial Of Qtorin™ Rapamycin In Cutaneous Venous Malformations
Brief: Palvella Therapeutics Announces Uplisting To The Nasdaq Global Market
Palvella Therapeutics' Q1 net loss widens on higher costs